new warnings, again, about using inhaled long-acting beta-agonists (Serevent, etc) for asthma

January 2009

Please see the FDA's new recommendations for the use of long-acting beta agonists

You'll see new warnings, again, about using inhaled long-acting beta-agonists (Serevent, etc) for asthma.

These drugs already have a black box warning about a possible increased risk of severe asthma attacks and death.

Too many patients are still using long-acting beta-agonists ALONE for asthma...instead of with an inhaled corticosteroid.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote